scholarly journals Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma

2018 ◽  
Vol 186 (1) ◽  
pp. 140-144 ◽  
Author(s):  
M. Junaid Hussain ◽  
Myra M. Robinson ◽  
Issam Hamadeh ◽  
Justin Arnall ◽  
Manisha Bhutani ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Combination Therapy ◽  
Refractory Multiple Myeloma

scholarly journals Efficacy of Combination Therapy with Glycyrrhizinate, Antiallergic Agent, and Low Dose Steroid for Lenalidomide-induced Skin Eruptions in a Patient with Refractory Multiple Myeloma

2012 ◽  
Vol 61 (3) ◽  
pp. 89-92
Author(s):  
Masafumi MATSUGUMA ◽  
Toru TAKAHASHI ◽  
Hiroyuki NAKAMURA ◽  
Sumie HIRAMATSU ◽  
Takashi YAMAGUCHI ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Combination Therapy ◽  
Low Dose ◽  
Refractory Multiple Myeloma ◽  
Antiallergic Agent

scholarly journals Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma

2018 ◽  
Vol 59 (11) ◽  
pp. 2588-2594 ◽  
Author(s):  
Ajai Chari ◽  
Sarah Larson ◽  
Beata Holkova ◽  
Robert F. Cornell ◽  
Cristina Gasparetto ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Combination Therapy ◽  
Phase 1 ◽  
Phase 1 Trial ◽  
Refractory Multiple Myeloma

Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

2007 ◽  
Vol 25 (25) ◽  
pp. 3892-3901 ◽  
Author(s):  
Robert Z. Orlowski ◽  
Arnon Nagler ◽  
Pieter Sonneveld ◽  
Joan Bladé ◽  
Roman Hajek ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Combination Therapy ◽  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
International Study ◽  
Phase Iii ◽  
Combination Group ◽  
Time To Progression ◽  
Refractory Multiple Myeloma ◽  
Grade 3

PurposeThis phase III international study compared the efficacy and safety of a combination of pegylated liposomal doxorubicin (PLD) plus bortezomib with bortezomib monotherapy in patients with relapsed or refractory multiple myeloma.Patients and MethodsSix hundred forty-six patients were randomly assigned to receive either intravenous bortezomib 1.3 mg/m2on days 1, 4, 8, and 11 of an every 21-days cycle, or the same bortezomib regimen with PLD 30 mg/m2on day 4.ResultsMedian time to progression was increased from 6.5 months for bortezomib to 9.3 months with the PLD + bortezomib combination (P = .000004; hazard ratio, 1.82 [monotherapy v combination therapy]; 95% CI, 1.41 to 2.35). The 15-month survival rate for PLD + bortezomib was 76% compared with 65% for bortezomib alone (P = .03). The complete plus partial response rate was 41% for bortezomib and 44% for PLD + bortezomib, a difference that was not statistically significant. Median duration of response was increased from 7.0 to 10.2 months (P = .0008) with PLD + bortezomib. Grade 3/4 adverse events were more frequent in the combination group (80% v 64%), with safety profiles consistent with the known toxicities of the two agents. An increased incidence in the combination group was seen of grade 3/4 neutropenia, thrombocytopenia, asthenia, fatigue, diarrhea, and hand-foot syndrome.ConclusionPLD with bortezomib is superior to bortezomib monotherapy for the treatment of patients with relapsed or refractory multiple myeloma. The combination therapy is associated with a higher incidence of grade 3/4 myelosuppression, constitutional symptoms, and GI and dermatologic toxicities.

Bortezomib, Doxorubicin and Dexamethasone (PAD) Combination Therapy for Chinese Relapsed or Refractory Multiple Myeloma.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4948-4948
Author(s):  
Yongqing Zhang ◽  
Guangxun Gao ◽  
Jishi Wang ◽  
Xiequn Chen
Keyword(s):  
Multiple Myeloma ◽  
Peripheral Neuropathy ◽  
Partial Response ◽  
Combination Therapy ◽  
Response Rate ◽  
Conflicts Of Interest ◽  
Complete Response ◽  
Extramedullary Plasmacytoma ◽  
Refractory Multiple Myeloma ◽  
Progression Of Disease

Abstract Abstract 4948 Objective To investigate the efficacy and safety of PAD (bortezomib, doxorubicin and dexamethasone) combination therapy for Chinese relapsed or refractory multiple myeloma (MM). Methods 31 patients with relapsed or refractory MM received two to eight 21-days cycles of PAD: comprising an intravenous bolus of bortezomib 1.3 mg/m2 (P1,N=13) or 1.0 mg/m2 (P2,N=18) on days 1, 4, 8, and 11, doxorubicin 10mg per day on days 1 to 4, along with dexamethasone 40mg on days 1-4. Response to PAD was evaluated according to International Myeloma Working Group Criteria (IMWG 2006), toxicity was graded according to NCI CTCAE v3.0. Results 25 patients (80.6%) achieved at least a partial response (PR), including complete response (CR) in 9 patients (29%), very good partial response (VGPR) in 7 patients (22.6%), PR in 9 patients (29%) and stable disease (SD) in 4 patients(12.9%), progression of disease (PD) in 2 patients (6.5%); median time to progression was 9.2 months, the median courses to achieve at least PR was 1.6(1-3) cycles, all of 7 patients with extramedullary plasmacytoma achieved at least PR after the first cycle of PAD, extramedullary plasmacytoma disappeared with 1-2 cycles of PAD. The efficacy was independent of traditional prognostic factors such asβ2-MG, Albumin,LDH and Hemoglobin which have previously influenced response to traditional chemotherapy. 1.5 year OS (Overall survival)of CR+VGPR group and PR group were 87.5% vs 46.7% (P=0.09). ≥PR response rate (CR +VGPR +PR) of P1AD and P2AD were 84.6% VS 77.8% (P= 0.501), CR+VGPR rate of P1AD and P2AD were 53.8% vs 50.0% (P=0.561 ). 1 year PFS(Progession-free survival) of P1AD and P2AD were 61.2% vs 55.6%(P=0.638), there were not difference between P1AD and P2AD in response rate(P= 0.501) and 1 year OS (P=0.872). Adverse events included thrombocytopenia in 15 patients ( 48.4% ), leukopenia in 8 patients(25.8%), peripheral neuropathy in 6 patients (19.4% ), varicella herpes zoster in 7 patients (22.6%), fatigue in 11 patients (35.5%) and diarrhea in 5 patients (16.1%), Thrombocytopenia and peripheral neuropathy of P1AD and P2AD were 46.2% vs 11.1%( P=0.037)and 53.8% vs 11.1%(P= 0.014).Common adverse reactions could be controlled with routine supportive treatmemt, one patient (3.2% ) died from respiratory failure during his fifth P1>AD. Conclusions PAD should be considered an appropriate treatment for Chinese relapsed or refractory MM, especially for MM with extramedullary plasmacytoma, its efficacy were independent of traditional prognosis factors, bortezomib dose reduction may reduce toxicities of PAD while retaining the efficacy. Disclosures No relevant conflicts of interest to declare.

scholarly journals A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

2009 ◽  
Vol 15 (3) ◽  
pp. 1069-1075 ◽  
Author(s):  
James R. Berenson ◽  
Ori Yellin ◽  
Ravi Patel ◽  
Herb Duvivier ◽  
Youram Nassir ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Combination Therapy ◽  
Phase I ◽  
Phase I Study ◽  
Refractory Multiple Myeloma

scholarly journals A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma

2008 ◽  
Vol 81 (4) ◽  
pp. 247-252 ◽  
Author(s):  
Marie von Lilienfeld-Toal ◽  
Corinna Hahn-Ast ◽  
Kerstin Furkert ◽  
Florian Hoffmann ◽  
Ralph Naumann ◽  
...  
Keyword(s):  
Systematic Review ◽  
Multiple Myeloma ◽  
Combination Therapy ◽  
Phase Ii ◽  
Phase Ii Trials ◽  
Refractory Multiple Myeloma

scholarly journals VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma

Leukemia ◽  
2008 ◽  
Vol 22 (7) ◽  
pp. 1419-1427 ◽  
Author(s):  
M Pineda-Roman ◽  
M Zangari ◽  
F van Rhee ◽  
E Anaissie ◽  
J Szymonifka ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Combination Therapy ◽  
Refractory Multiple Myeloma ◽  
Highly Effective
Sign in / Sign up

Export Citation Format

Share Document